The FDA Vaccines and Related Biological Products Advisory Committee will meet today from 8:30 am-5:00 pm ET to discuss and make recommendations on strain selection for the periodic updated Covid-19 vaccines for the 2023-2024 vaccine campaign.
The discussion topic will be:
“Based on the evidence and other considerations presented, please
discuss selection of a specific XBB lineage (e.g., XBB.1.5 or
XBB.1.16 or XBB.2.3) for inclusion in the 2023-2024 Formula of
COVID-19 vaccines in the U.S.”
The voting question will be:
“For the 2023-2024 Formula of COVID-19 vaccines in the U.S., does the
committee recommend a periodic update of the current vaccine composition to
a monovalent XBB-lineage?”
UPDATE: The committee upvoted the question unanimously. The word “periodic” was removed from the question. A September 2023 time frame was expected for availability of the new vaccine.
Go Retire Psychiatrist 